MIMPARA 90mg Price

Overview

Welcome to Dwaey, specifically on MIMPARA 90mg Tablets/Film-coated page.
This medicine contains an important and useful components, as it consists of Cinacalcet (as HCl).
MIMPARA 90mg is available in the market in concentration 90mg/Tablet and in the form of Tablets/Film-coated.

AMGEN EUROPE B.V. is the producer of MIMPARA 90mg and it is imported from NETHERLANDS, The most popular alternatives of MIMPARA 90mg are listed downward .

Mode Of Action

Cinacalcet is a calcimimetic agent. It lowers parathyroid hormone (PTH) secretion by increasing the sensitivity of the calcium-sensing receptor of the parathyroid gland to activation by extracellular calcium. PTH reduction leads to concomitant decrease in serum calcium and phosphorus concentrations.

Indication

• Hyperparathyroidism
• Hypercalcemia
• Parathyroid carcinoma

Precaution

Moderate-to-severe hepatic impairment, CV diseases. Not indicated for chronic kidney disease patients who are not receiving dialysis. Do not initiate Cinacalcet in hypocalcaemic patients. For secondary hyperparathyroidism, measure serum calcium and phosphorus (prior to- and within 1 wk after initiation/dose adjustment; mthly during maintenance) and iPTH (prior to- and within 1-4 wk after initiation/dosage adjustment; every 1-3 mth during maintenance). iPTH levels should drawn at least 12 hr after Cinacalcet dosing. For parathyroid carcinoma and primary parathyroidism, measure serum calcium prior-to and within 1 wk after initiation/dose adjustment; and every 2-3 mth during maintenance. Vitamin D sterols, calcium-containing phosphate binder and/or adjustment of calcium contents of dialysis fluid can be used to raise serum calcium in the event of hypocalcaemia. Reduce dose or withhold therapy if hypocalcaemia persists; may reinstate treatment at the next lowest dose after calcium levels normalised. Significant reduction in serum calcium may lower seizure threshold. Adynamic bone disease may develop if iPTH level is suppressed to < 100 pg/mL. May decrease total and free testosterone levels. Safety and efficacy not established in patients ?18 yr. Pregnancy and lactation. Lactation: excretion in milk unknown/not recommended

Side Effects

• >10% Secondary Parathyroidism Diarrhea (20%)
• Nausea (19%)
• Vomiting (15%)
• Myalgia (14%) 1-10% Secondary Parathyroidism Dizziness (8%)
• Hypertension (5%)
• Access infection (4%)
• Anorexia (4%)
• Asthenia (4%)
• Noncardiac chest pain (4%)
• Seizures 1.4% Frequency Not Defined Parathyroid CA Nausea/vomiting
• Hypocalcemia Potentially Fatal: Hypersensitivity reaction including angioedema.

Contra indication

Hypersensitivity.

Pregnancy and lactation

Pregnancy category: C

Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks